Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
Y. Nakanisihi (Hiroshima, Japan), Y. Horimasu (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Hattori (Hiroshima, Japan). IL-18 binding protein as a noble biomarker for idiopathic pulmonary fibrosis. 818

Member's Comments

No comment yet.

Related content which might interest you: NHLRC2 mRNA and protein expression in idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Translational and other aspects of idiopathic interstitial pneumonia Year: 2021 Plasma protein signature of idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Translational research to bridge the need within clinical decision making Year: 2013 Serum surfactant proteins-A and -D as biomarkers in idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 19: 439-446 Year: 2002 VEGF expression does not differentiate between idiopathic pulmonary fibrosis and pulmonary sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 574s Year: 2007 Serum surfactant protein D may predict the effect of pirfenidone in idiopathic pulmonary fibrosis Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis and rarities Year: 2013 Serum levels of surfactant proteins in patients with combined pulmonary fibrosis and emphysema (CPFE) Source: International Congress 2015 – IPF pathogenesis Year: 2015 IL-6 and IL-8 in stable and exacerbated IPF patients and their association to outcome Source: International Congress 2016 – ILD: from the bench to the bedside Year: 2016 Role of interleukin-10 in idiopathic pulmonary fibrosis Source: Eur Respir J 2004; 23: 179-180 Year: 2004 Serum progranulin levels in idiopathic pulmonary fibrosis and other interstitial lung diseases Source: International Congress 2018 – Idiopathic interstital pneumonias other than idiopathic pulmonary fibrosis (IPF) Year: 2018 Does IFN-g slow progression of idiopathic pulmonary fibrosis (IPF)? Source: Eur Respir J 2005; 26: Suppl. 49, 335s Year: 2005 High mobility group box protein 1 (HMGB1) production in highly vascularized alveolar lesions causes acute exacerbation in idiopathic pulmonary fibrosis Source: Annual Congress 2005 - Progresses in lung fibrosis Year: 2005 The circulating metabolome in idiopathic pulmonary fibrosis (IPF) Source: International Congress 2019 – The evolving field of idiopathic interstitial pneumonia Year: 2019 Differential expression of IL-33 and HMGB1 in the lungs of stable cystic fibrosis patients Source: Eur Respir J 2014; 44: 802-805 Year: 2014 TNF-a and IL-10 control macrophage expression of CXCL13, a prognostic biomarker of idiopathic pulmonary fibrosis Source: International Congress 2018 – Back to basics and translational research in idiopathic interstitial pneumonias Year: 2018 The role of chemokines and cytokines in lung fibrosis Source: Eur Respir Rev 2008; 17: 151-156 Year: 2008 NLRP3 inflammasome expression in idiopathic pulmonary fibrosis and rheumatoid lung Source: Eur Respir J 2016; 47: 910-918 Year: 2016 Serum IGFBP2 as a marker of idiopathic pulmonary fibrosis Source: International Congress 2015 – Interstitial lung diseases II Year: 2015 Relationship between MIF and cellular pattern in BAL of patients with sarcoidosis, systemic sclerosis, idiopathic pulmonary fibrosis Source: Eur Respir J 2003; 22: Suppl. 45, 377s Year: 2003 PD-L1 expression in patients with idiopathic pulmonary fibrosis. Source: Virtual Congress 2021 – Biomarkers and e-health in idiopathic interstitial pneumonia Year: 2021 Decreased BCL-2 expression in alveolar macrophages of patients with idiopathic pulmonary fibrosis Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010